Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q13416
UPID:
ORC2_HUMAN
Alternative names:
-
Alternative UPACC:
Q13416; Q13204; Q53TX5
Background:
Origin recognition complex subunit 2 (ORC2) plays a pivotal role in DNA replication initiation, binding origins of replication in an ATP-dependent manner. Despite the lack of identified specific DNA sequences for replication origins, ORC2's involvement in assembling the pre-replication complex is crucial. It also interacts with histone modifications, such as H3K9me3, H3K20me3, and H4K27me3, and stabilizes both LRWD1 and ORC3 against proteasomal degradation.
Therapeutic significance:
Understanding the role of Origin recognition complex subunit 2 could open doors to potential therapeutic strategies.